Publications

These publications are examples of research made possible with data from CanPath and its regional cohorts.

2024

Cohort profile: the CARTaGENE Cohort Nutrition Study (Quebec, Canada)

Authors: V. Ho, I. Csizmadi, B. A. Boucher, M. McInerney, C. Boileau, N. Noisel, Y. Payette, P. Awadalla, A. Koushik

The researchers aimed to address emerging nutritional epidemiological research questions, using data from the CARTaGENE cohort. Dietary information was collected making it a rich resource for the exploration of diet in the etiology of many health outcomes. They found that dietary intake and quality varied among participants but generally met recommended nutrient levels. Along with other findings, the Canadian Healthy Eating Index 2005 (C-HEI) scores were higher among never smokers, those with higher education, and those with more physical activity compared to current smokers, less than high school education, and those with lower physical activity.

Read Publication
2024

Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Authors: Eric Y. Stutheit-Zhao, Enrique Sanz-Garcia; Zhihui (Amy) Liu; Derek Wong; Kayla Marsh; Albiruni R. Abdul Razak; Anna Spreafico; Philippe L. Bedard; Aaron R. Hansen; Stephanie Lheureux; Dax Torti; Bernard Lam; Shih Yu Cindy Yang; Justin Burgener; Ping Luo; Yong Zeng; Nicholas Cheng; Philip Awadalla; Scott V. Bratman; Pamela S. Ohashi; Trevor J. Pugh; Lillian L. Siu

The researchers investigated pharmacodynamic biomarkers of response to pembrolizumab in 106 patients with advanced solid tumors. Researchers analyzed genome-wide methylation and fragment-length profiles using cfMeDIP-seq in 204 plasma samples from 87 patients. Two cohorts of normal control cfMeDIP-seq data, including 72 healthy women from the Ontario Health Study, were used for comparison. CSM and FLS are strongly correlated with tumor-informed ctDNA levels. The study found that early kinetics of cancer-specific methylation (CSM) predicted overall survival and progression-free survival, independent of tumor type, PD-L1, and tumor mutation burden. The researchers’ tumor-naïve mutation-agnostic ctDNA approach integrating methylomics and fragmentomics could predict outcomes in patients treated with pembrolizumab.

Read Publication
2024

The mediating role of health behaviors in the association between depression, anxiety and cancer incidence: An individual participant data meta-analysis

Authors: Kuan-Yu Pan, Lonneke van Tuijl , Maartje Basten, Judith J M Rijnhart, Alexander de Graeff, Joost Dekker , Mirjam I Geerlings, Adriaan Hoogendoorn, Adelita V Ranchor, Roel Vermeulen, Lützen Portengen, Adri C Voogd, Jessica Abell, Philip Awadalla, Aartjan T F Beekman, Ottar Bjerkeset, Andy Boyd, Yunsong Cui, Philipp Frank, Henrike Galenkamp, Bert Garssen, Sean Hellingman, Monika Hollander, Martijn Huisman, Anke Huss, Melanie R Keats, Almar A L Kok, Steinar Krokstad, Flora E van Leeuwen, Annemarie I Luik, Nolwenn Noisel, Yves Payette, Brenda W J H Penninx , Susan Picavet, Ina Rissanen, Annelieke M Roest, Judith G M Rosmalen, Rikje Ruiter, Robert A Schoevers, David Soave, Mandy Spaan, Andrew Steptoe, Karien Stronks, Erik R Sund, Ellen Sweeney, Alison Teyhan, Emma L Twait, Kimberly D van der Willik, Femke Lamers

Researchers investigated how various health behaviors might mediate the relationships between depression, anxiety, and the onset of different types of cancer. They conducted individual participant data meta-analyses using participants from 18 cohorts from the Psychosocial Factors and Cancer Incidence consortium.The cohorts analyzed included the Atlantic Partnership for Tomorrow’s Health, Ontario Health Study, and CARTaGENE. The findings suggested that smoking serves as a mediating factor that connects depression and anxiety with lung cancer and other cancers related to smoking.

Read Publication
2024

Psychosocial factors, health behaviors and risk of cancer incidence: Testing interaction and effect modification in an individual participant data meta-analysis

Authors: Maartje Basten, Kuan-Yu Pan, Lonneke A vanTuijl, Alexander de Graeff, Joost Dekker, Adriaan W Hoogendoorn, Femke Lamers, Adelita V Ranchor, Roel Vermeulen, Lützen Portengen, Adri C Voogd, Jessica Abell, Philip Awadalla, Aartjan T.F. Beekman, Ottar Bjerkeset, Andy Boyd, Yunsong Cui, Philipp Frank, Henrike Galenkamp, Bert Garssen, Sean Hellingman, Martijn Huisman, Anke Huss, Melanie R. Keats, Almar A.L. Kok, Steinar Krokstad, Flora E. van Leeuwen, Annemarie I. Luik, NolwennNoisel, Yves Payette, Brenda W.J.H. Penninx, Ina Rissanen, Annelieke M. Roest, Judith G.M. Rosmalen, Rikje Ruiter, Robert A. Schoevers, David Soave, Mandy Spaan, Andrew Steptoe, Karien Stronks, Erik R. Sund, Ellen Sweeney, Emma L. Twait, Alison Teyhan, W.M. Monique Verschuren, Kimberly D. van der Willik, Mirjam I. Geerlings

Researchers determined whether psychosocial factors interact with or modify the effects of health behaviors, such as smoking and alcohol use, in relation to cancer incidence. Data were used from 22 cohorts, including the Ontario Health Study, Atlantic Partnership for Tomorrow’s Health, and CARTaGENE. After exploring 744 combinations of psychosocial factors, the researchers found no evidence that psychosocial factors interacted with or modified health behaviors related to cancer incidence.

Read Publication
2023

The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023

Authors: Tanya J. Murphy, Hanna Swail, Jaspreet Jain, Maureen Anderson, Philip Awadalla, Lesley Behl, Patrick E. Brown, Carmen L. Charlton, Karen Colwill, Steven J. Drews, Anne-Claude Gingras, Deena Hinshaw, Prabhat Jha, Jamil N. Kanji, Victoria A. Kirsh, Amanda L. S. Lang, Marc-André Langlois, Stephen Lee, Antoine Lewin, Sheila F. O'Brien, Chantale Pambrun, Kimberly Skead, David A. Stephens, Derek R. Stein, Graham Tipples, Paul G. Van Caeseele, Timothy G. Evans, Olivia Oxlade, Bruce D. Mazer, David L. Buckeridge

This study used data from the COVID-19 Immunity Task Force, which includes CanPath data, to track the prevalence of SARS-CoV-2 antibodies in the Canadian population over the pre-vaccination period, the vaccine rollout, and the emergence of the Omicron variant. By March 2023, over three-quarters of the population had detectable antibodies, with the most substantial increases seen after the arrival of the Omicron variant. However, variations in immunity by age and geography highlight the importance of tailoring public health policies and clinical decisions to local patterns of population immunity, considering factors like potential antibody decline and the emergence of new variants that might evade immunity.

Read Publication
2023

Depression, anxiety, and the risk of cancer: An individual participant data meta-analysis

Authors: Lonneke A van Tuijl, Maartje Basten, Kuan-Yu Pan, Roel Vermeulen, Lützen Portengen, Alexander de Graeff, Joost Dekker, Mirjam I Geerlings, Adriaan Hoogendoorn, Femke Lamers, Adri C Voogd, Jessica Abell, Philip Awadalla, Aartjan T F Beekman, Ottar Bjerkeset, Andy Boyd, Yunsong Cui, Philipp Frank, Henrike Galenkamp, Bert Garssen, Sean Hellingman, Martijn Huisman, Anke Huss, Trynke R de Jong, Melanie R Keats, Almar A L Kok, Steinar Krokstad, Flora E van Leeuwen, Annemarie I Luik, Nolwenn Noisel, N Charlotte Onland-Moret, Yves Payette, Brenda W J H Penninx, Ina Rissanen, Annelieke M Roest, Rikje Ruiter, Robert A Schoevers, David Soave, Mandy Spaan, Andrew Steptoe, Karien Stronks, Erik R Sund, Ellen Sweeney, Emma L Twait, Alison Teyhan, W M Monique Verschuren, Kimberly D van der Willik, Judith G M Rosmalen, Adelita V Ranchor

Researchers performed meta-analyses within the Psychosocial Factors and Cancer Incidence (PSY-CA) consortium to develop a stronger foundation for addressing associations between depression, anxiety, and the incidence of various cancer types. They found that depression and anxiety are not related to increased risk for most cancer outcomes, except for lung and smoking-related cancers.

Read Publication
2023

Provincial variation in colorectal cancer screening adherence in Canada; evidence from the Canadian Partnership for Tomorrow’s Health

Authors: Maryam Darvishian, Amina Moustaqim-Barrette, Philip Awadalla, Parveen Bhatti, Philippe Broet, Kelly McDonald, Rachel A. Murphy, Kimberly Skead, Robin Urquhart, Jennifer Vena, Trevor J. B. Dummer

The researchers sought to assess regional variation in screening uptake, identify factors to non-adherence to screening, and estimate adherence to screening in those with differing risk profiles. Using national CanPath data, they found adherence suboptimal amongst Canadians and noticed variation by region.

Read Publication
2023

Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases

Authors: Wejdan M Alenezi, Caitlin T Fierheller, Corinne Serruya, Timothée Revil, Kathleen K Oros, Deepak N Subramanian, Jeffrey Bruce, Dan Spiegelman, Trevor Pugh, Ian G Campbell, Anne-Marie Mes-Masson, Diane Provencher, William D Foulkes, Zaki El Haffaf, Guy Rouleau, Luigi Bouchard, Celia M T Greenwood, Jiannis Ragoussis, Patricia N Tonin

Researchers investigated families with a history of ovarian cancer that couldn’t be explained by known genetic risk factors. Using healthy controls from CARTaGENE, they applied a targeted gene approach and found rare genetic variants in DNA repair pathway genes, particularly in ERCC5, EXO1, FANCC, NEIL1, and NTHL1, in a significant portion of these families.

Read Publication
2022

Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease

Authors: Wei Zhou, Masahiro Kanai, Kuan-Han H Wu, Humaira Rasheed, Kristin Tsuo, Jibril B Hirbo, Ying Wang, Arjun Bhattacharya, Huiling Zhao, Shinichi Namba, Ida Surakka, Brooke N Wolford, Valeria Lo Faro, Esteban A Lopera-Maya, Kristi Läll, Marie-Julie Favé, Juulia J Partanen, Sinéad B Chapman, Juha Karjalainen, Mitja Kurki, Mutaamba Maasha, Ben M Brumpton, Sameer Chavan, Tzu-Ting Chen, Michelle Daya, Yi Ding, Yen-Chen A Feng, Lindsay A Guare, Christopher R Gignoux, Sarah E Graham, Whitney E Hornsby, Nathan Ingold, Said I Ismail, Ruth Johnson, Triin Laisk, Kuang Lin, Jun Lv, Iona Y Millwood, Sonia Moreno-Grau, Kisung Nam, Priit Palta, Anita Pandit, Michael H Preuss, Chadi Saad, Shefali Setia-Verma, Unnur Thorsteinsdottir, Jasmina Uzunovic, Anurag Verma, Matthew Zawistowski, Xue Zhong, Nahla Afifi, Kawthar M Al-Dabhani, Asma Al Thani, Yuki Bradford, Archie Campbell, Kristy Crooks, Geertruida H de Bock, Scott M Damrauer, Nicholas J Douville, Sarah Finer, Lars G Fritsche, Eleni Fthenou, Gilberto Gonzalez-Arroyo, Christopher J Griffiths, Yu Guo, Karen A Hunt, Alexander Ioannidis, Nomdo M Jansonius, Takahiro Konuma, Ming Ta Michael Lee, Arturo Lopez-Pineda, Yuta Matsuda, Riccardo E Marioni, Babak Moatamed, Marco A Nava-Aguilar, Kensuke Numakura, Snehal Patil, Nicholas Rafaels, Anne Richmond, Agustin Rojas-Muñoz, Jonathan A Shortt, Peter Straub, Ran Tao, Brett Vanderwerff, Manvi Vernekar, Yogasudha Veturi, Kathleen C Barnes, Marike Boezen, Zhengming Chen, Chia-Yen Chen, Judy Cho, George Davey Smith, Hilary K Finucane, Lude Franke, Eric R Gamazon, Andrea Ganna, Tom R Gaunt, Tian Ge, Hailiang Huang, Jennifer Huffman, Nicholas Katsanis, Jukka T Koskela, Clara Lajonchere, Matthew H Law, Liming Li, Cecilia M Lindgren, Ruth J F Loos, Stuart MacGregor, Koichi Matsuda, Catherine M Olsen, David J Porteous, Jordan A Shavit, Harold Snieder, Tomohiro Takano, Richard C Trembath, Judith M Vonk, David C Whiteman, Stephen J Wicks, Cisca Wijmenga, John Wright, Jie Zheng, Xiang Zhou, Philip Awadalla, Michael Boehnke, Carlos D Bustamante, Nancy J Cox, Segun Fatumo, Daniel H Geschwind, Caroline Hayward, Kristian Hveem, Eimear E Kenny, Seunggeun Lee, Yen-Feng Lin, Hamdi Mbarek, Reedik Mägi, Hilary C Martin, Sarah E Medland, Yukinori Okada, Aarno V Palotie, Bogdan Pasaniuc, Daniel J Rader, Marylyn D Ritchie, Serena Sanna, Jordan W Smoller, Kari Stefansson, David A van Heel, Robin G Walters, Sebastian Zöllner; Biobank of the Americas; Biobank Japan Project; BioMe; BioVU; CanPath - Ontario Health Study; China Kadoorie Biobank Collaborative Group; Colorado Center for Personalized Medicine; deCODE Genetics; Estonian Biobank; FinnGen; Generation Scotland; Genes & Health Research Team; LifeLines; Mass General Brigham Biobank; Michigan Genomics Initiative; National Biobank of Korea; Penn Medicine BioBank; Qatar Biobank; QSkin Sun and Health Study; Taiwan Biobank; HUNT Study; UCLA ATLAS Community Health Initiative; Uganda Genome Resource; UK Biobank; Alicia R Martin, Cristen J Willer, Mark J Daly, Benjamin M Neale

The Global Biobank Meta-analysis Initiative is a collaborative network of 23 biobanks, representing more than 2.2M consented participants with genetic data linked to electronic health records. This collaborative effort will improve genome-wide association studies’ power for diseases, benefit understudied diseases, and improve risk prediction.

Read Publication
2022

Harnessing the power of data linkage to enrich the cancer research ecosystem in Canada

Authors: Robin Urquhart, Philip Awadalla, Parveen Bhatti, Trevor Dummer, Simon Gravel, Jennifer Vena, Riaz Alvi, Philippe Broet, Cynthia Kendell, Victoria Kirsh, Guillaume Lettre, Kimberly Skead, Grace Shen-Tu, Ellen Sweeney, Donna Turner

This abstract discusses a project aimed at linking cancer registry and administrative health data to Canada’s largest population health study, the Canadian Partnership for Tomorrow’s Health (CanPath). The project seeks to enrich the cancer research ecosystem in Canada by providing researchers with a comprehensive dataset that includes genetics, environment, lifestyle, and behaviour data. The linked data will be made available through a cloud-based solution called the CanPath Data Safe Haven, which is accessible to researchers through secure access. The project will address concerns related to the accessibility of cancer data in Canada, bring more value to existing data, and support an enhanced understanding of the impacts of cancer on marginalized populations.

Read Publication